Sign in

You're signed outSign in or to get full access.

Dina

Vice President and Equity Research Analyst at Bank of America

Dina is a Vice President and Equity Research Analyst at Bank of America, specializing in the consumer sector with a focus on retail and apparel companies. She covers specific firms such as Nike, Lululemon, VF Corporation, and Gap Inc., boasting a strong performance track record with a 68% success rate on TipRanks, ranking in the top 10% of analysts, and generating average returns of 14.2% per rating. Dina joined Bank of America in 2018 after previous roles at Barclays and UBS starting her career in 2010, bringing over 14 years of experience in equity research. She holds Series 7, 63, and 86/87 FINRA licenses, along with an MBA from NYU Stern School of Business.

Dina's questions to Amylyx Pharmaceuticals (AMLX) leadership

Question · Q4 2025

Dina, on behalf of Jason Gerberry, asked if clinicians are more focused on a reduction in level 3 hypoglycemic events versus the regulatory composite endpoint, and for expectations on how events should skew at baseline between level 2 and level 3.

Answer

Co-CEO Josh Cohen explained that level 2 events signify severe symptoms and high risk of progressing to level 3 (incapacitation), which is why clinicians view both as critical and value the composite endpoint. He noted that previous studies showed slightly more level 2 than level 3 events, and they often occurred together.

Ask follow-up questions

Fintool

Fintool can predict Amylyx Pharmaceuticals logo AMLX's earnings beat/miss a week before the call